CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Reports

We found 7237 result(s)

Providing Appropriate Virtual Care Within and Beyond the Pandemic: Considerations for Policy-Makers

Event Date: May 5, 2021
Result type: Events

The COVID-19 pandemic has definitely affected many different aspects of the Canadian health care system — including the widespread adoption of virtual care. Demand for virtual care is unlikely to diminish over the immediate and long term; therefore, many people are wondering how to best optimize virtual care to ensure its sustainability and its ...

macitentan and tadalafil (TBC)

Last Updated: April 22, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: macitentan and tadalafil
Indications: For the long-term treatment of pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to reduce morbidity in patients of WHO functional class (FC) II or III whose PAH is either idiopathic or heritable or associated with connective tissue disease or congenital heart disease. Macitentan and tadalafil can be used in patients who are currently treated concomitantly with macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets.

  • Brand Name: TBC
  • Manufacturer: Janssen Inc.
  • Project Number: SR0690-000
  • Project Status: Pending
  • Submission Type: Initial

dupilumab (Dupixent)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: dupilumab
Indications: Dupixent is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.

  • Brand Name: Dupixent
  • Manufacturer: Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
  • Project Number: SR0667-000
  • Project Status: Active
  • Submission Type: Initial

risdiplam (Evrysdi)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: risdiplam
Indications: ​For the treatment of spinal muscular atrophy (SMA) in patients 2 months and older.

  • Brand Name: Evrysdi
  • Manufacturer: Hoffmann La-Roche Ltd.
  • Project Number: SR0661-000
  • Project Status: Active
  • Submission Type: Initial

satralizumab (Enspryng)

Last Updated: December 22, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: satralizumab
Indications: ENSPRYNG (satralizumab) is indicated as monotherapy or in combination with immunosuppressive therapy (IST) for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in adult and adolescent patients who are anti-aquaporin 4 (AQP4) seropositive. ENSPRYNG is not intended for acute treatment of an NMOSD relapse.

  • Brand Name: Enspryng
  • Manufacturer: Hoffmann-La Roche Limited
  • Project Number: SR0663-000
  • Project Status: Active
  • Submission Type: Initial

amifampridine (Ruzurgi)

Last Updated: December 24, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: amifampridine
Indications: Indicated for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS) in patients 6 years of age and older.

  • Brand Name: Ruzurgi
  • Manufacturer: Médunik Canada Inc.
  • Project Number: SR0660-000
  • Project Status: Active
  • Submission Type: Initial

infliximab (Remsima)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: infliximab
Indications: Use in combination with methotrexate for the reduction in signs and symptoms, inhibition of the progression of structural damage and improvement in physical function in adult patients with moderately to severely active rheumatoid arthritis.

  • Brand Name: Remsima
  • Manufacturer: Celltrion Healthcare Co., Ltd
  • Project Number: SR0659-000
  • Project Status: Active
  • Submission Type: Initial

alpelisib (Piqray)

Last Updated: April 21, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: alpelisib
Indications: ​Piqray (alpelisib), in combination with fulvestrant, is indicated for the treatment of postmenopausal women and men, with hormone receptor-positive, HER2-negative, PIK3CA mutated advanced or metastatic breast cancer after disease progression following an endocrine-based regimen.

  • Brand Name: Piqray
  • Manufacturer: Novartis Pharmaceuticals Canada Inc.
  • Project Number: PC0247-000
  • Project Status: Received
  • Submission Type: Initial

encorafenib and binimetinib (Braftovi and Mektovi)

Last Updated: December 21, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: encorafenib and binimetinib
Indications: ​Braftovi (encorafenib): In combination with binimetinib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test. Mektovi (binimetinib): In combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test.

  • Brand Name: Braftovi and Mektovi
  • Manufacturer: Pfizer Canada ULC
  • Project Number: PC0232-000
  • Project Status: Active
  • Submission Type: Initial

tucatinib (Tukysa )

Last Updated: April 21, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: tucatinib
Indications: ​Tucatinib is indicated in combination with trastuzumab and capecitabine for treatment of patients with locally advanced unresectable or metastatic HER2-positive breast cancer, including patients with brain metastases, who have received prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine, separately or in combination.

  • Brand Name: Tukysa
  • Manufacturer: Seagen Canada Inc.
  • Project Number: PC0243-000
  • Project Status: Active
  • Submission Type: Initial